A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy

Trial Profile

A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Robatumumab (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2016 This trial is completed in Netherlands, Hungary and UK (31/08/2011) along with Germany and Italy as per European Clinical Trials Database record.
    • 14 Mar 2016 According to ClinicalTrials.gov record, the study was prematurely terminated for strategic reasons, not for a safety concern.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top